Biotechnology

ZeZentalis Pharma

ZeZentalis Pharma released FY2026 Q1 earnings on May 12 (EST), actual EPS USD -0.5031 (forecast USD -0.4725)

Zentalis Pharmaceuticals Reports Q1 2026 Financial Results and Clinical Progress

Zentalis Pharmaceuticals Begins Third-Stage ASPENOVA Trial to Assess Azenosertib Efficacy

Zentalis Pharmaceuticals to Present Platinum-Resistant Ovarian Cancer Study Abstract at ASCO Annual Meeting

ZeZentalis Pharma released FY2025 Annual Earnings on March 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.91 (forecast USD -1.8237)

ZeZentalis Pharma released FY2025 Q4 earnings on March 26 (EST), actual EPS USD -0.4943 (forecast USD -0.4262)

ZeZentalis Pharma released FY2025 9 Months earnings on November 10 (EST), actual revenue USD 0, actual EPS USD -1.0468

ZeZentalis Pharma released FY2025 Q3 earnings on November 10 (EST), actual EPS USD -0.3699 (forecast USD -0.48)

Zentalis Pharmaceuticals Announces Development of WEE1 Inhibitor for Ovarian and Other Tumor Types

ZeZentalis Pharma released FY2025 Q2 earnings on August 6 (EST), actual EPS USD -0.3732 (forecast USD -0.5085)

ZeZentalis Pharma released FY2025 Semi-Annual earnings on August 6, 2025 (EST), actual revenue USD 0, actual EPS USD -1.0461

Zentalis Pharmaceuticals Grants Incentive Allowance

Zentalis Holds Annual General Meeting

Zentalis Pharmaceuticals Rated by Brokers, Director Ups Stock

Zentalis Announces Development of WEE1 Inhibitor for Ovarian Cancer and Other Tumors

MPM Bioimpact LLC Reduces Holdings in Zentalis Pharmaceuticals

ZeZentalis Pharma released FY2025 Q1 earnings on May 14 (EST), actual EPS USD -0.6735 (forecast USD -0.6265)

Zentalis Pharmaceuticals Director Acquires Common Stock

Zentalis Pharmaceuticals Begins Second Phase Clinical Trials for Ovarian Cancer Drug

Zentalis Pharmaceuticals' Abstract Approved for ASCO Annual Meeting

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ZNTL

LABU

ARKG

SBIO

Wedbush analyst maintained a Hold rating on Zentalis Pharmaceuticals today and set a price target of $4.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Wedbush, Zentalis Pharmaceuticals also received a Hold from Morgan Stanley’s Michael Ulz in a report issued today. However, on the same day, Oppenheimer reiterated a Buy rating on Zentalis Pharmaceuticals (NASDAQ: ZNTL).

Tip Ranks

SPDR S&P Biotech

iShares US Pharma

Direxion S&P Biotech Bull 3X

VG Health

VanEck Biotech ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares Biotechnology ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Morgan Stanley

Oppenheimer

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Wedbush Keeps Their Hold Rating on Zentalis Pharmaceuticals (ZNTL)

Analyst Andres Y. Maldonado from H.C. Wainwright has reiterated a Buy rating on Zentalis Pharmaceuticals, maintaining a price target of $10. The rating is based on Zentalis’ advancements with azenosertib and its WEE1-focused strategy, including a 400mg once-daily dosing regimen supported by positive interim DENALI data. The company aims to position azenosertib as a targeted treatment for Cyclin E1-positive platinum-resistant ovarian cancer patients. With a cash balance of approximately $212M, Zentalis is well-positioned for upcoming catalysts, justifying the price target and rating.

ImmunityBio

Verastem

CG oncology

Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts

Earnings Watch

ZeZentalis Pharma | 10-Q: FY2026 Q1 Revenue: USD 0

BAYRY

MDGL

Bayer has agreed to acquire Perfuse Therapeutics for up to $2.45 billion, with $300 million upfront. Madrigal Pharmaceuticals secured a global license for ARO-PNPLA3, a siRNA therapy, for $25 million upfront and up to $975 million in milestones. Zentalis Pharmaceuticals has dosed the first patient in a Phase III trial for a WEE1 inhibitor in ovarian cancer. Brooke Ervin discusses the challenges of translating real-world evidence into actionable clinical decisions in urology, emphasizing the need for better integration of data into clinical workflows.

Pharmexec

Bayer

Madrigal Pharma

Bayer AG

ArrowHead Pharma

Bayer Aktiengesellschaft

<![CDATA[Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial]]>

Zentalis Pharmaceuticals has initiated the Aspenova Phase III trial, dosing its first patient to evaluate azenosertib, an oral WEE1 inhibitor, against chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer. This trial aims to confirm whether biomarker selection enhances treatment outcomes in a challenging setting with limited options. Approximately 420 patients will be enrolled, with the primary endpoint being progression-free survival. The study aligns with FDA guidelines for potential accelerated approval, although key limitations include the absence of peer-reviewed data and safety information. Zentalis expects topline results from the Denali study by late 2026.

<![CDATA[First Patient Dosed with Azenosertib in Aspenova Phase III Trial for Treatment of Ovarian Cancer]]>

Zentalis Pharmaceuticals has initiated the Phase 3 ASPENOVA trial by dosing the first patient. This trial will evaluate azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer, comparing it to standard chemotherapy. Approximately 420 patients will be enrolled, with the primary endpoint being progression-free survival (PFS). The trial is designed to support full approval in line with FDA requirements, following positive interim results from the DENALI Part 2a analysis.

TradingView

Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC